| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
CURRENT COMMENTARY |
Department of Pathology, College of Physicians and Surgeons of Columbia University, New York, New York; National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland; Student Health Services, University of California at Santa Barbara, Santa Barbara, California; Department of Obstetrics and Gynecology, University of Arizona, Arizona Cancer Center, Tucson, Arizona; Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts; Department of Obstetrics and Gynecology, Tufts University and New England Medical Center, Boston, Massachusetts; Marti Nelson Cancer Foundation, Hood River, Oregon; University of Connecticut School of Medicine, Farmington, Connecticut; and American Cancer Society, Atlanta, Georgia
Address reprint requests to: Address correspondence to: Thomas C. Wright Jr, MD, Room 16-404, P&S Building, 630 West 168th Street, New York, NY 10032; e-mail: tcw1{at}columbia.edu.
Human papillomavirus (HPV) DNA testing was recently approved by the Food and Drug Administration for use as an adjunct to cytology for cervical cancer screening. To help provide guidance to clinicians and patients when using HPV DNA testing as an adjunct to cervical cytology for screening, a workshop was cosponsored by the National Institutes of Health–National Cancer Institute, American Society of Colposcopy and Cervical Pathology (ASCCP), and American Cancer Society. Consensus was reached based on a literature review, expert opinion, and unpublished results from large ongoing screening studies. The conclusions of the workshop were that HPV DNA testing may be added to cervical cytology for screening in women aged 30 years or more. Women whose results are negative by both HPV DNA testing and cytology should not be rescreened before 3 years. Women whose results are negative by cytology, but are high-risk HPV DNA positive, are at a relatively low risk of having high-grade cervical neoplasia, and colposcopy should not be performed routinely in this setting. Instead, HPV DNA testing along with cervical cytology should be repeated in these women at 6 to 12 months. If test results of either are abnormal, colposcopy should then be performed. This guidance should assist clinicians in utilizing HPV DNA testing in an effective manner, while minimizing unnecessary evaluations and treatments.
This article has been cited by other articles:
|
|
 |
|
  P. E. Castle Invited Commentary: Is Monitoring of Human Papillomavirus Infection for Viral Persistence Ready for Use in Cervical Cancer Screening? Am. J. Epidemiol., May 15, 2008; (2008) kwn037v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Gravitt, M. Schiffman, D. Solomon, C. M. Wheeler, and P. E. Castle A Comparison of Linear Array and Hybrid Capture 2 for Detection of Carcinogenic Human Papillomavirus and Cervical Precancer in ASCUS-LSIL Triage Study Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1248 - 1254. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C. Ginocchio, D. Barth, and F. Zhang Comparison of the Third Wave Invader Human Papillomavirus (HPV) Assay and the Digene HPV Hybrid Capture 2 Assay for Detection of High-Risk HPV DNA J. Clin. Microbiol., May 1, 2008; 46(5): 1641 - 1646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Vanslyke, J. Baum, V. Plaza, M. Otero, C. Wheeler, and D. L. Helitzer HPV and Cervical Cancer Testing and Prevention: Knowledge, Beliefs, and Attitudes Among Hispanic Women Qual Health Res, May 1, 2008; 18(5): 584 - 596. [Abstract] [PDF]
|
|
|
|
 |
|
 J. D. Goldhaber-Fiebert, N. K. Stout, J. A. Salomon, K. M. Kuntz, and S. J. Goldie Cost-Effectiveness of Cervical Cancer Screening With Human Papillomavirus DNA Testing and HPV-16,18 Vaccination J Natl Cancer Inst, March 5, 2008; 100(5): 308 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Guo, Y. Gong, M. Deavers, E. G. Silva, Y. J. Jan, D. E. Cogdell, R. Luthra, E. Lin, H. C. Lai, W. Zhang, et al. Evaluation of a Commercialized In Situ Hybridization Assay for Detecting Human Papillomavirus DNA in Tissue Specimens from Patients with Cervical Intraepithelial Neoplasia and Cervical Carcinoma J. Clin. Microbiol., January 1, 2008; 46(1): 274 - 280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Castle, P. E. Gravitt, D. Solomon, C. M. Wheeler, and M. Schiffman Comparison of Linear Array and Line Blot Assay for Detection of Human Papillomavirus and Diagnosis of Cervical Precancer and Cancer in the Atypical Squamous Cell of Undetermined Significance and Low-Grade Squamous Intraepithelial Lesion Triage Study J. Clin. Microbiol., January 1, 2008; 46(1): 109 - 117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Sokolova, A. Algeciras-Schimnich, M. Song, S. Sitailo, F. Policht, B. R. Kipp, J. S. Voss, K. C. Halling, A. Ruth, W. King, et al. Chromosomal Biomarkers for Detection of Human Papillomavirus Associated Genomic Instability in Epithelial Cells of Cervical Cytology Specimens J. Mol. Diagn., November 1, 2007; 9(5): 604 - 611. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Coutlee, D. Rouleau, G. Ghattas, C. Hankins, S. Vezina, P. Cote, J. Macleod, A. de Pokomandy, D. Money, S. Walmsley, et al. Confirmatory Real-Time PCR Assay for Human Papillomavirus (HPV) Type 52 Infection in Anogenital Specimens Screened for HPV Infection with the Linear Array HPV Genotyping Test J. Clin. Microbiol., November 1, 2007; 45(11): 3821 - 3823. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-H. Mayrand, E. Duarte-Franco, I. Rodrigues, S. D. Walter, J. Hanley, A. Ferenczy, S. Ratnam, F. Coutlee, E. L. Franco, and the Canadian Cervical Cancer Screening Trial Study Human Papillomavirus DNA versus Papanicolaou Screening Tests for Cervical Cancer N. Engl. J. Med., October 18, 2007; 357(16): 1579 - 1588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Naucler, W. Ryd, S. Tornberg, A. Strand, G. Wadell, K. Elfgren, T. Radberg, B. Strander, O. Forslund, B.-G. Hansson, et al. Human Papillomavirus and Papanicolaou Tests to Screen for Cervical Cancer N. Engl. J. Med., October 18, 2007; 357(16): 1589 - 1597. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hildesheim, R. Herrero, S. Wacholder, A. C. Rodriguez, D. Solomon, M. C. Bratti, J. T. Schiller, P. Gonzalez, G. Dubin, C. Porras, et al. Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting Infection: A Randomized Trial JAMA, August 15, 2007; 298(7): 743 - 753. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Kim, K. M. Kuntz, N. K. Stout, S. Mahmud, L. L. Villa, E. L. Franco, and S. J. Goldie Multiparameter Calibration of a Natural History Model of Cervical Cancer Am. J. Epidemiol., July 15, 2007; 166(2): 137 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. Bock and B. M. Kwan Encouragement of Patient Self-management and Adherence through Use of a Computerized Tracking System for Cervical and Colon Cancer Screening J Am Board Fam Med, May 1, 2007; 20(3): 316 - 319. [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Castle, J. Dockter, C. Giachetti, F. A.R. Garcia, M. K. McCormick, A. L. Mitchell, E. B. Holladay, and D. P. Kolk A Cross-sectional Study of a Prototype Carcinogenic Human Papillomavirus E6/E7 Messenger RNA Assay for Detection of Cervical Precancer and Cancer Clin. Cancer Res., May 1, 2007; 13(9): 2599 - 2605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Tiro, H. I. Meissner, S. Kobrin, and V. Chollette What Do Women in the U.S. Know about Human Papillomavirus and Cervical Cancer? Cancer Epidemiol. Biomarkers Prev., February 1, 2007; 16(2): 288 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Gillison Human Papillomavirus and Prognosis of Oropharyngeal Squamous Cell Carcinoma: Implications for Clinical Research in Head and Neck Cancers J. Clin. Oncol., December 20, 2006; 24(36): 5623 - 5625. [Full Text] [PDF]
|
|
|
|
|
|
P. E. Castle, M. Sadorra, F. Garcia, E. B. Holladay, and J. Kornegay Pilot Study of a Commercialized Human Papillomavirus (HPV) Genotyping Assay: Comparison of HPV Risk Group to Cytology and Histology J. Clin. Microbiol., November 1, 2006; 44(11): 3915 - 3917. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Gage, V. W. Hanson, K. Abbey, S. Dippery, S. Gardner, J. Kubota, M. Schiffman, D. Solomon, J. Jeronimo, and for The ASCUS LSIL Triage Study (ALTS) Group Number of Cervical Biopsies and Sensitivity of Colposcopy Obstet. Gynecol., August 1, 2006; 108(2): 264 - 272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Irwin, D. Montano, D. Kasprzyk, L. Carlin, C. Freeman, R. Barnes, N. Jain, J. Christian, and C. Wolters Cervical Cancer Screening, Abnormal Cytology Management, and Counseling Practices in the United States Obstet. Gynecol., August 1, 2006; 108(2): 397 - 409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Castle, A. Aftab, G. Saint-Jean, and L. Mendez Detection of carcinogenic human papillomavirus in specimens collected with a novel self-sampling device. J. Clin. Microbiol., June 1, 2006; 44(6): 2158 - 2159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K McCaffery, J Waller, J Nazroo, and J Wardle Social and psychological impact of HPV testing in cervical screening: a qualitative study. Sex. Transm. Inf., April 1, 2006; 82(2): 169 - 174. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hildesheim and A. B. de Gonzalez Etiology and prevention of cervical adenocarcinomas. J Natl Cancer Inst, March 1, 2006; 98(5): 292 - 293. [Full Text] [PDF]
|
|
|
|
|
|
L. Denny, L. Kuhn, M. De Souza, A. E. Pollack, W. Dupree, and T. C. Wright Jr Screen-and-Treat Approaches for Cervical Cancer Prevention in Low-Resource Settings: A Randomized Controlled Trial JAMA, November 2, 2005; 294(17): 2173 - 2181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. T. Dresang Colposcopy: An Evidence-Based Update J Am Board Fam Med, September 1, 2005; 18(5): 383 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Noller Cervical Cytology Screening and Evaluation Obstet. Gynecol., August 1, 2005; 106(2): 391 - 397. [Full Text] [PDF]
|
|
|
|
|
|
P. E. Castle, D. Solomon, M. Schiffman, C. M. Wheeler, and for the ALTS Group Human Papillomavirus Type 16 Infections and 2-Year Absolute Risk of Cervical Precancer in Women With Equivocal or Mild Cytologic Abnormalities J Natl Cancer Inst, July 20, 2005; 97(14): 1066 - 1071. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Khan, P. E. Castle, A. T. Lorincz, S. Wacholder, M. Sherman, D. R. Scott, B. B. Rush, A. G. Glass, and M. Schiffman The Elevated 10-Year Risk of Cervical Precancer and Cancer in Women With Human Papillomavirus (HPV) Type 16 or 18 and the Possible Utility of Type-Specific HPV Testing in Clinical Practice J Natl Cancer Inst, July 20, 2005; 97(14): 1072 - 1079. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Kim, T. C. Wright, and S. J. Goldie Cost-effectiveness of Human Papillomavirus DNA Testing in the United Kingdom, The Netherlands, France, and Italy J Natl Cancer Inst, June 15, 2005; 97(12): 888 - 895. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Franceschi and G. M. Clifford Re: A Study of the Impact of Adding HPV Types to Cervical Cancer Screening and Triage Tests J Natl Cancer Inst, June 15, 2005; 97(12): 938 - 939. [Full Text] [PDF]
|
|
|
|
|
|
T. G. Harris, R. D. Burk, J. M. Palefsky, L. S. Massad, J. Y. Bang, K. Anastos, H. Minkoff, C. B. Hall, M. C. Bacon, A. M. Levine, et al. Incidence of Cervical Squamous Intraepithelial Lesions Associated With HIV Serostatus, CD4 Cell Counts, and Human Papillomavirus Test Results JAMA, March 23, 2005; 293(12): 1471 - 1476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Schiffman, M. J. Khan, D. Solomon, R. Herrero, S. Wacholder, A. Hildesheim, A. C. Rodriguez, M. C. Bratti, C. M. Wheeler, R. D. Burk, et al. A Study of the Impact of Adding HPV Types to Cervical Cancer Screening and Triage Tests J Natl Cancer Inst, January 19, 2005; 97(2): 147 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Castle Cervical Cancer Screening Among Women Without a Cervix JAMA, October 6, 2004; 292(13): 1550 - 1551. [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Harper Why Am I Scared of HPV? CA Cancer J Clin, September 1, 2004; 54(5): 245 - 247. [Full Text] [PDF]
|
|
|
|
|
|
R. Anhang, A. Goodman, and S. J. Goldie HPV Communication: Review of Existing Research and Recommendations for Patient Education CA Cancer J Clin, September 1, 2004; 54(5): 248 - 259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 HPV DNA Testing as an Adjunct to Cervical Cytology Journal Watch (General), February 27, 2004; 2004(227): 4 - 4. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
